Nektar (NKTR) R&D chief sells 3,867 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky reported a planned stock sale under a pre-arranged Rule 10b5-1 trading plan. On January 20, 2026, he sold 3,867 shares of Nektar common stock at a weighted average price of $35.67 per share, through multiple trades within a price range of $35.17 to $36.23. After this transaction, he directly held 21,354 shares of Nektar common stock.

Insider Trade Summary

Net Seller: 3,867 shares ($137,936)

Net Sell 1 txn

Insider Zalevsky Jonathan

Role Chief R&D Officer

Sold 3,867 shs ($138K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,867	$35.67	$138K

Holdings After Transaction: Common Stock — 21,354 shares (Direct)

Footnotes (1)

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2025. This transaction was executed in multiple trades at prices ranging from $35.17 to $36.23 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zalevsky Jonathan

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/20/2026		S		3,867	D	$35.67(2)	21,354	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $35.17 to $36.23 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NKTR Chief R&D Officer Jonathan Zalevsky report?

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported a sale of 3,867 shares of the company’s common stock in a Form 4 filing.

When did Jonathan Zalevsky’s NKTR stock sale occur and at what price?

The sale took place on January 20, 2026, at a weighted average price of $35.67 per share, with individual trades executed between $35.17 and $36.23.

How many Nektar Therapeutics shares does Jonathan Zalevsky own after this transaction?

Following the reported sale, Jonathan Zalevsky directly holds 21,354 shares of Nektar Therapeutics common stock.

Was Jonathan Zalevsky’s NKTR stock sale under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Jonathan Zalevsky on May 16, 2025.

What does the price range in Jonathan Zalevsky’s NKTR sale mean?

The filing notes the sale was executed in multiple trades at prices ranging from $35.17 to $36.23, and the reported $35.67 is the weighted average sale price.

Does the Form 4 indicate indirect ownership or other entities for this NKTR transaction?

No. The transaction is reported as direct ownership (D), with no indication in the footnotes that another entity, trust, or partnership holds voting or investment authority.